PMID- 18555460
OWN - NLM
STAT- MEDLINE
DCOM- 20081118
LR  - 20080616
IS  - 1107-0625 (Print)
IS  - 1107-0625 (Linking)
VI  - 13
IP  - 2
DP  - 2008 Apr-Jun
TI  - Preoperative chemotherapy in early-stage (stage IB-IIIA) resectable non small 
      cell lung cancer. Is it justified?
PG  - 161-8
AB  - Only 20-30% of patients with non small cell lung cancer (NSCLC) present with 
      early-stage disease at the time of diagnosis and may benefit by surgical 
      resection. Five-year survival in early-stage disease varies from 38 to 57% for 
      stage IB and from 13 to 23% for stage IIIA according to the clinical and 
      pathological assessment of the patients. Occult micrometastatic disease already 
      present in many patients with resectable NSCLC at the time of diagnosis and 
      surgical treatment leads to local and distant disease recurrence. Therefore a 
      more systemic approach should be considered in early-stage disease. The role of 
      adjuvant chemotherapy has already been established in this field. Within the past 
      decade attention has been focused on the possible beneficial effects of 
      preoperative chemotherapy considering that patients' compliance to the induction 
      treatment can be very high with eventual eradication of micrometastatic disease 
      and primary tumor downstaging. In this review we present the currently available 
      data on induction chemotherapy followed by surgery in early-stage (stages 
      IB-IIIA) NSCLC with a fundamental question to be answered: is this approach 
      justified in current clinical practice?
FAU - Prokakis, Ch
AU  - Prokakis Ch
AD  - Department of Cardiothoracic Surgery, University of Patras, Patras, Greece.
FAU - Koletsis, E N
AU  - Koletsis EN
FAU - Apostolakis, E
AU  - Apostolakis E
FAU - Chatzimichalis, A
AU  - Chatzimichalis A
FAU - Dougenis, D
AU  - Dougenis D
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Cyprus
TA  - J BUON
JT  - Journal of B.U.ON. : official journal of the Balkan Union of Oncology
JID - 100883428
SB  - IM
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology/surgery
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/pathology/surgery
MH  - Neoplasm Staging
MH  - Risk Assessment
RF  - 32
EDAT- 2008/06/17 09:00
MHDA- 2008/11/19 09:00
CRDT- 2008/06/17 09:00
PHST- 2008/06/17 09:00 [pubmed]
PHST- 2008/11/19 09:00 [medline]
PHST- 2008/06/17 09:00 [entrez]
PST - ppublish
SO  - J BUON. 2008 Apr-Jun;13(2):161-8.